Ann: Lumos Expands Henry Schein FebriDx Distribution Partnership, page-8

I'm aware of that my friend - however - (and CLIA is 100% relevant seeing as it involves the biggest market in the world will be a perpetual anchor until the extra 220,000 POC clients can become customers) - the future is the reader / IP, and the reader / IP only.

My thoughts are that it will be Febridx that gets purchased, and that LDX will become an IP / medical tech company only.

I know the rewards are less, but the risk is reduced to nearly zero.

The market likes that sort of risk!

Thoughts? (genuinely, as you are a bit of a light amongst some of the more...how can I say it, less-researched stock holders )

Bought in yesterday on the back of the IP / tech aspect - and expecting a slow, steady climb upwards over the next 12 months, as the market finally notices the company is being run differently, and that risk / reward ratios have massively improved.

Cheers